{"schema_version":"secwatch.filing_event.v1","accession":"0001801170-23-000059","form_type":"8-K","ticker":"CLOV","cik":"0001801170","company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.295255+00:00","generated_at":"2026-06-12T02:33:16.429438+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Clover Health posts first quarterly Adjusted EBITDA profit of $10M; insurance MCR improves to 77.2%","bullets":["Q2 revenue $513.6M; insurance revenue up 17% YoY to $314.4M; net loss $28.8M vs $104.4M loss YoY.","Insurance MCR improved to 77.2% from 92.1% YoY; non-insurance MCR 99.6% vs 106.0%.","Adjusted EBITDA profit $10.0M compared to loss of $83.9M in Q2 2022; first quarterly positive.","FY 2023 guidance improved: insurance MCR 83%-85%, Adjusted EBITDA ($70M)-($120M).","CEO Andrew Toy cites operational efficiencies and Clover Assistant R&D; CFO confident in FY 2024 EBITDA profitability without new capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001801170-23-000059","json":"https://secwatch.observer/filing/0001801170-23-000059.json","markdown":"https://secwatch.observer/filing/0001801170-23-000059.md","text":"https://secwatch.observer/filing/0001801170-23-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1801170/000180117023000059/0001801170-23-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1801170/000180117023000059/clov-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:33:16.429438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2d8dd5ec339a2e7721e389248c2076947faa093","claim":"CLOVER HEALTH INVESTMENTS, CORP. /DE reported the quarter ended June 30, 2023 results: revenue $513.6 million, net income $28.8 million. Guidance reaffirmed.","evidence_excerpt":"For the second quarter 2023, the Company reported revenue of $513.6 million and net loss of $28.8 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1801170/000180117023000059/0001801170-23-000059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$513.6 million"},{"label":"Net income","value":"$28.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}